Jenburkt Pharmaceuticals standalone net profit rises 27.05% in the March 2026 quarter

Sales rise 8.72% to Rs 44.63 crore

Net profit of Jenburkt Pharmaceuticals rose 27.05% to Rs 10.85 crore in the quarter ended March 2026 as against Rs 8.54 crore during the previous quarter ended March 2025. Sales rose 8.72% to Rs 44.63 crore in the quarter ended March 2026 as against Rs 41.05 crore during the previous quarter ended March 2025.

For the full year,net profit rose 8.36% to Rs 34.74 crore in the year ended March 2026 as against Rs 32.06 crore during the previous year ended March 2025. Sales rose 11.24% to Rs 168.74 crore in the year ended March 2026 as against Rs 151.69 crore during the previous year ended March 2025.

Particulars	Quarter Ended			Year Ended
	Mar. 2026	Mar. 2025	% Var.	Mar. 2026	Mar. 2025	% Var.
Sales	44.63	41.05	9	168.74	151.69	11
OPM %	31.93	26.46	-	25.92	26.63	-
PBDT	18.47	12.63	46	53.58	46.66	15
PBT	17.66	11.84	49	50.47	43.93	15
NP	10.85	8.54	27	34.74	32.06	8

Powered by Capital Market - Live News